APUS vs KMB · $2.4M cap vs P/E 19, rev $8.35B
Apimeds Pharmaceuticals US, Inc. (APUS) versus Kimberly-Clark Corporation (KMB) — a side-by-side from cached financials, not a winner call.
Apimeds Pharmaceuticals US, Inc. (APUS) is a drug manufacturers - specialty & generic company listed on US.
Kimberly-Clark Corporation (KMB) is a household & personal products company listed on US.
APUS does not have a complete income-statement cache yet.
Latest reported KMB revenue for 2026-06-30 was $8.35B. Net income was $1.01B. KMB currently screens at market cap $32.88B and trailing P/E 19.2.
APUS currently screens at market cap $2.4M. KMB currently screens at market cap $32.88B and trailing P/E 19.2.
Not investment advice. Open the APUS and KMB stock pages for the full models.
Not investment advice.